Sani-Care Salon Products, Inc. – 673747

by Pill Pals Customer Service | Mar 31, 2025 | News

Delivery Method: VIA Electronic Mail Product: Drugs Recipient: Recipient Name Mr. Mingzhong Su Recipient Title President Sani-Care Salon Products, Inc. 51 Curtis Court, Ste. BCartersville, GA 30120United States Issuing Office: Division of Pharmaceutical Quality...

Recall: Medtronic Removes Aortic Root Cannula for Loose Material Risk

by Pill Pals Customer Service | Mar 31, 2025 | News

This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it.Affected ProductProduct Names: DLP Aortic Root...

The Bakery Group Issues Allergen Alert on Undeclared Milk, Soy and Yellow FD&C #5 In Specific Bread and Hamburger Buns

by Pill Pals Customer Service | Mar 28, 2025 | News

Summary Company Announcement Date: March 25, 2025 FDA Publish Date: March 28, 2025 Product Type: Food & Beverages Bakery Product/Mix Allergens Reason for Announcement: Recall Reason Description May contain undeclared milk, soy and yellow FD&C # 5 Company...

FDA approves durvalumab for muscle invasive bladder cancer

by Pill Pals Customer Service | Mar 28, 2025 | News

On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle...

FDA expands Pluvicto’s prostate cancer indication

by Pill Pals Customer Service | Mar 28, 2025 | News

On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with prostate-specific membrane antigen (PSMA)-positive metastatic...

FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

by Pill Pals Customer Service | Mar 28, 2025 | News

For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A...

Questions about Blood

by Pill Pals Customer Service | Mar 28, 2025 | News

FDA is responsible for ensuring the safety of the Nation’s blood supply. While a blood supply with zero risk of transmitting infectious disease may not be possible, there are several measures taken by FDA to protect and enhance the safety of blood products.The...

New Drug Applications (NDAs)

by Pill Pals Customer Service | Mar 28, 2025 | News

The following products are regulated as New Drug Applications (NDAS): Solutions used in the collection of blood and plasma donations.List of New Drug ApplicationsRelated Information Content current as of: 02/17/2023...